The molecular pharmacology of organic anion transporters: from DNA to FDA?
about
Role of the plasma membrane transporter of organic cations OCT1 and its genetic variants in modern liver pharmacologyThe organic anion transporter (OAT) family: a systems biology perspectiveOlfactory mucosa-expressed organic anion transporter, Oat6, manifests high affinity interactions with odorant organic anionsOrganic anion and cation transporter expression and function during embryonic kidney development and in organ culture modelsTenofovir renal proximal tubular toxicity is regulated by OAT1 and MRP4 transportersNovel slc22 transporter homologs in fly, worm, and human clarify the phylogeny of organic anion and cation transporters.Multiple organic anion transporters contribute to net renal excretion of uric acidHalf-life of serum elimination of perfluorooctanesulfonate,perfluorohexanesulfonate, and perfluorooctanoate in retired fluorochemical production workersA three-dimensional model of human organic anion transporter 1: aromatic amino acids required for substrate transport.Transcriptome-based reconstructions from the murine knockout suggest involvement of the urate transporter, URAT1 (slc22a12), in novel metabolic pathwaysHandling of Drugs, Metabolites, and Uremic Toxins by Kidney Proximal Tubule Drug Transporters.Use of in vitro transporter assays to understand hepatic and renal disposition of new drug candidates.Multi-level analysis of organic anion transporters 1, 3, and 6 reveals major differences in structural determinants of antiviral discriminationOrganic anion transporter 3 contributes to the regulation of blood pressure.Pharmacogenetics of chronic pain and its treatment.Multispecific drug transporter Slc22a8 (Oat3) regulates multiple metabolic and signaling pathways.Organic anion transporter 3 inhibitors as potential novel antihypertensives.Toward a systems level understanding of organic anion and other multispecific drug transporters: a remote sensing and signaling hypothesis.The transport of anti-HIV drugs across blood-CNS interfaces: summary of current knowledge and recommendations for further research.A review of multifunctional nanoemulsion systems to overcome oral and CNS drug delivery barriers.Transporters that translocate nucleosides and structural similar drugs: structural requirements for substrate recognition.Regulation of human organic anion transporter 4 by progesterone and protein kinase C in human placental BeWo cells.Structural variation governs substrate specificity for organic anion transporter (OAT) homologs. Potential remote sensing by OAT family members.Conformational changes of the multispecific transporter organic anion transporter 1 (OAT1/SLC22A6) suggests a molecular mechanism for initial stages of drug and metabolite transport.Overlapping in vitro and in vivo specificities of the organic anion transporters OAT1 and OAT3 for loop and thiazide diuretics.Decreased renal organic anion secretion and plasma accumulation of endogenous organic anions in OAT1 knock-out mice.Uricosuric agents decrease the plasma urate level in rats by concomitant treatment with topiroxostat, a novel xanthine oxidoreductase inhibitor.Quantitative structure-activity relationship analysis of a series of human renal organic anion transporter inhibitors.Multiple-approach studies to assess anthocyanin bioavailability
P2860
Q27026858-ACBF1A8B-497E-4AB9-9A35-BE28194111C9Q28085671-429808D5-958F-4521-8A21-ECA6A2FCE753Q33263153-F6517268-E8DE-4835-A918-EED1E09E121EQ33674894-D5B97D3A-3CE7-4E6E-8100-85397EAF5500Q33845879-48BD7ABA-CE48-4541-B3C4-F9F77A8CF0E1Q34309854-14D05552-A042-4098-B4C5-FAA7A962B1B5Q34470733-633145BD-97CA-456D-B5F7-C4CC3D5FCED7Q34680365-A008B26B-08FF-4F7A-ADAF-AB4EEBC87CAAQ35740999-7825F7AB-2819-4630-A986-50A0B26F8E76Q35910587-78F422BA-8222-450C-B39D-7808B5E08FD9Q36250282-7BC22CE6-A0D7-41C1-88A2-096A99F4EF3EQ36544962-5081F928-14E3-4723-BF0E-FCC6C74B0D51Q36704152-317470DE-90AC-4057-9415-1065868A46C5Q36842435-6A2BFC73-E567-425C-A4C3-4CFB62B5756CQ36900075-364F2F1D-D33A-473E-90DE-5BFB620368BCQ37193094-719D16A5-1EE4-42AB-91B9-632A0B662B10Q37313541-E90A8DDF-73F1-4CA3-B5F1-20E81B336E8FQ37314370-72828767-66EC-477C-88EF-30BE2D28106EQ37379470-23095575-DF96-4CFF-B5E9-5992692E3630Q37798553-315DA3C8-D081-4B90-A458-39B0D44460DDQ37834510-C45994C4-DA31-40DD-A5EC-78F6988E4589Q40162697-15212CDB-B780-4C2C-81B8-50EB0BB239DCQ41905911-7CCA68ED-7862-4AAB-9D1E-C4F0A3E14AC9Q46071440-D67840B6-E04B-4AB1-84CF-4956800D0B78Q46096113-5EE2BC63-0AFC-4F16-840D-75077CFBC616Q46312451-1C64523A-258F-4A56-A205-EC3EC8883050Q47896324-5A9CFE6B-849D-4676-A805-26377F4B7A6AQ51340586-46D6D963-7CD7-486A-87EF-E18BA98F2E21Q57687891-34739D0F-7AE3-4AA3-8ABB-FBC8982D36CD
P2860
The molecular pharmacology of organic anion transporters: from DNA to FDA?
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
The molecular pharmacology of organic anion transporters: from DNA to FDA?
@ast
The molecular pharmacology of organic anion transporters: from DNA to FDA?
@en
type
label
The molecular pharmacology of organic anion transporters: from DNA to FDA?
@ast
The molecular pharmacology of organic anion transporters: from DNA to FDA?
@en
prefLabel
The molecular pharmacology of organic anion transporters: from DNA to FDA?
@ast
The molecular pharmacology of organic anion transporters: from DNA to FDA?
@en
P2093
P356
P1476
The molecular pharmacology of organic anion transporters: from DNA to FDA?
@en
P2093
Kevin T Bush
Rosemary V Sampogna
Sanjay K Nigam
Satish A Eraly
Vibha Bhatnagar
P304
P356
10.1124/MOL.65.3.479
P577
2004-03-01T00:00:00Z